Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through studyMarc Ferrante, Luciana Teixeira de Campos, Geert D’Haens et al.|The Lancet|2024Cited by 107
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trialBrian G. Feagan, Dermot McGovern, Bruce E Sands et al.|The Lancet. Gastroenterology & hepatology|2025Cited by 28
Evaluation and Management of Glucocorticoid-Induced Adrenal Insufficiency in IBD: An Expert OpinionCindy C Y Law, Takayuki Yamamoto, Christopher Ma et al.|Inflammatory Bowel Diseases|2025Cited by 3